65,437 trials
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)…
Gastric Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Docetaxel When Given in Combination With Oxaliplatin and Fluorouracil (Phase I) — 50 mg/m2
Osteoarthritis · Falls, Accidental
Primary: Participant Adherence to Intervention — 5 Participants
Addiction
Primary: Urine Toxicology — 16.1; 17; 14.9 average cocaine positive urine samples
Vascular Reaction to Medications
Primary: ED50 After Phenylephrine — 172; 310 ng/min
Cardiac Surgery
Primary: Any Major Morbidity/30-day Mortality — 46; 82 Participants — p=0.0043
Schizophrenia
Primary: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score — -15.367…
Epilepsy
Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants
Scleroderma
Primary: Cochin Hand Functional Scale — 19.24 units on a scale
Chronic Hepatitis C(CHC)
Primary: Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 63.3; 20.0; 71.4…
Staphylococcal Skin Infection · Abscess · Furunculosis
Primary: Number of Participants With Incidence of SSTI at 3 Months After Decolonization — 23; 23 Participants — p=0.757
Pediatric Obesity
Primary: Change in Child BMIz — -0.21; 0.26; -.05; 0.41 BMIz
Obesity
Primary: Serum Maximum Concentrations for Piperacillin — 136; 190; 237; 332 milligrams per liter
Lung Cancer · Esophageal Cancer
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Scores. — 43.05; 51.51; 48.64; 50.74 units on a scale — p=<0.05
Lymphoma, B-Cell
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants